

The FAMHP financing law: fees

Dear Madam, Dear Sir,

The FAMHP financing law was published on 26 March 2018 and entered into force on 5 April 2018. We refer you to the FAMHP's communication on this matter on the FAMHP website.

You will find hereunder an overview of fees. These amounts will be applied to all requests that come in from 05/04/2018. After processing your request, you will receive an invoice indicating the amount to be paid.

In case of fundamental questions concerning prices, within the DG Inspection, you should contact Mr. Patrice Corbière: patrice.corbriere@afmps.be

For practical questions, please contact : drugprecursor@afmps.be

Request for a licence /registration for manufacture, placing on market, offer for sale, possession, supplying of scheduled substances, pursuant to the Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors, Article 3 and Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade in drug precursors between the Union and third countries, Articles 6 and 7) , in accordance with article 1 "Drugs Act".	287,69€
Request for an import authorisation for scheduled substances pursuant to the Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade in drug precursors between the Union and third countries, Article 20), in accordance with article 1 "Drugs Act".	84,02€
Request for an export authorisation for scheduled substances, pursuant to the Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade in drug of trade in drug precursors between the Union and third countries, Article 12 in accordance with article 1 "Drugs Act".	84,02€
Request for a "letter of no objection" (declaration certifying that relevant substances are not subjected to an import or export authorisation) in accordance with article 1 "Drugs Act" : LONO	72,61€

Please note that these amounts are not anticipatively paid but will be invoiced once the authorization has been issued.

Drug Precursors Unit.